CD274 and cancer: Given that tumors as well as immunosuppressive cells in their microenvironment, like MDSC, frequently upregulate PD-L1 as a strategy to dampen efficient T-cell responses, the introduction of antibodies interfering with such pathways (“checkpoint inhibitors”) has been a major breakthrough in the treatment of certain cancers (33, 34).